[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367753-105":59,"doc-detail-367753-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-role-and-mechanism-of-arid1a-in-immunotherapy-of-gastric-cancer","The role and mechanism of ARID1A in immunotherapy of gastric cancer","","This study clarifies the clinical significance of ARID1A expression in gastric cancer and explains how ARID1A regulates PD-L1 during immunotherapy response. ARID1A expression was analyzed in 205 gastric adenocarcinoma specimens and 30 matched paracancerous tissues using immunohistochemistry, complemented by ARID1A-depleted GC cell line experiments. Results show ARID1A deficiency in tumors, poorer survival, and altered PD-1 inhibitor efficacy via PI3K/AKT-mediated PD-L1 upregulation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-role-and-mechanism-of-arid1a-in-immunotherapy-of-gastric-cancer/367753/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-role-and-mechanism-of-arid1a-in-immunotherapy-of-gastric-cancer/367753.png","ImageObject",300,407,{"name":92,"@type":93},"Mabel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study objective regarding ARID1A in gastric cancer?","Question",{"text":112,"@type":113},"To determine the clinical significance of ARID1A expression in gastric cancer and to explore its mechanistic role in regulating PD-L1 during immunotherapy response.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did researchers assess ARID1A and PD-L1 in patient samples?",{"text":117,"@type":113},"They analyzed ARID1A expression in 205 gastric adenocarcinoma specimens and 30 matched paracancerous tissues, evaluating ARID1A and PD-L1 profiles by immunohistochemical analysis.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanistic link did the study identify between ARID1A and immunotherapy response?",{"text":121,"@type":113},"ARID1A depletion promoted tumor aggressiveness and increased PD-L1 expression through activation of the PI3K/AKT signaling pathway, influencing the efficacy of PD-1 inhibitors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367753,1790207452,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971474920318,"https://ap-avatar.wpscdn.com/avatar/74000ee537e6b0ca360?x-image-process=image/resize,m_fixed,w_180,h_180&k=1788430171632181674","Clinical and Experimental Medicine (2025) 25:277 [https://doi.org/10.1007/s10238-025-01778-w](https://doi.org/10.1007/s10238-025-01778-w)  \nThe role and mechanism of ARID1A in immunotherapy of gastric cancer  \nWenting He1 · Yue Chen1 · Xue Yao1 · Jun Wu1 · Danxia Zhu1 · Jian Wang1 · Lu Jiang1 · Yueping Shen2 · Dachuan Zhang3 · Jingting Jiang4  \nReceived: 6 June 2025 / Accepted: 17 June 2025 / Published online: 6 August 2025 © The Author(s) 2025  \nAbstract  \nObjective This study aimed to clarify the clinical significance of ARID1A expression in gastric cancer (GC) and explore its mechanistic role in regulating PD-L1 expression during immunotherapy response.  \nMethods A comprehensive analysis of ARID1A expression was conducted in 205 gastric adenocarcinoma specimens and 30 matched paracancerous tissues. ARID1A and PD-L1 expression profiles were assessed through immunohistochemical analysis. Functional studies using ARID1A-depleted GC cell lines were performed to uncover the underlying molecular mechanisms, with a particular focus on the PI3K/AKT signaling pathway.  \nResults ARID1A deficiency was predominantly observed in GC tissues (42.4%) compared to paracancerous tissues (13.3%, P \u003C 0.01) . This loss was significantly associated with aggressive clinicopathological features and reduced overall survival (median: 21.2 vs. 49.0 months, P \u003C 0.001) . Multivariate analysis identified ARID1A as an independent prognostic indicator. ARID1A status significantly influenced the efficacy of PD-1 inhibitors (P \u003C 0.01), with its loss predicting an enhanced therapeutic response. Mechanistically, ARID1A depletion promoted tumor aggressiveness and increased PD-L1 expression via activation of the PI3K/AKT pathway.  \nConclusion Our findings demonstrate that ARID1A deficiency, while linked to poor prognosis, paradoxically enhances sensitivity to immunotherapy in GC. The newly identified ARID1A-PI3K/AKT-PD-L1 axis represents a promising therapeutic target, highlighting the potential utility of PI3K/AKT inhibitors in treating ARID1A-deficient GC.  \nKeywords ARID1A · PD-L1 · Gastric cancer · PI3K/AKT Pathway · Immunotherapy  \nAbbreviations  \nWenting He, Yue Chen and Xue Yao have contributed equally to this work and should be considered co-first authors.  \n* Dachuan Zhang [zhangdachuan@suda.edu.cn](zhangdachuan@suda.edu.cn)  \n* Jingting Jiang [jiangjingting@suda.edu.cn](jiangjingting@suda.edu.cn)  \n1 Present Address: Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou 213003, Jiangsu Province, China  \n2 Department of Epidemiology and Biostatistics, School of Public Health, Medical College of Soochow University, 199 Renai Road, Suzhou 215123, P. R. China  \n3 Present Address: Department of Pathology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou 213003, Jiangsu Province, China  \n4 Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China  \nARID1A  \nGC  \nPD-1  \nCPS  \nPD-L1  \nROC  \nAUC  \nICIs  \nOS  \nPFS  \nEBV  \nMSI-H  \nTMB  \nTILs  \nSWI/SNF  \nMMR  \nSTR  \nAT-rich interaction domain 1A Gastric cancer  \nProgrammed cell death protein-1 Combined positive score Programmed cell death ligand-1 Receiver operating characteristic Area under curve  \nImmune checkpoint inhibitors Overall survival  \nProgression free survival Epstein–Barr virus Microsatellite instability-high Tumor mutation burden  \nTumor infiltrating lymphocytes Mating-type switching/sucrose  \nnon-fermenting Mismatch repair Short tandem repeats  \nCR Complete response  \nPR Partial response  \nSD Stable disease  \nPD Progressive disease  \nsi-RNA Small interfering RNAsh-RNA Short hairpin RNA TCGA The cancer genome atlas  \nIntroduction  \nGastric cancer (GC), originating from the gastric mucosal epithelium, is one of the most prevalent malignancies of the digestive tract and ranks as the third leading cause of cancerrelated deaths worldwide. Over 70% of new GC cases and ","cbCaio9g21ftmHoB","https://ap.wps.com/l/cbCaio9g21ftmHoB","pdf",2197298,17,"English","# Abstract\n## Objective\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Gastric cancer background and risk factors\n## Immune checkpoint inhibitors and PD-1/PD-L1 axis","[{\"question\":\"What was the study objective regarding ARID1A in gastric cancer?\",\"answer\":\"To determine the clinical significance of ARID1A expression in gastric cancer and to explore its mechanistic role in regulating PD-L1 during immunotherapy response.\"},{\"question\":\"How did researchers assess ARID1A and PD-L1 in patient samples?\",\"answer\":\"They analyzed ARID1A expression in 205 gastric adenocarcinoma specimens and 30 matched paracancerous tissues, evaluating ARID1A and PD-L1 profiles by immunohistochemical analysis.\"},{\"question\":\"What mechanistic link did the study identify between ARID1A and immunotherapy response?\",\"answer\":\"ARID1A depletion promoted tumor aggressiveness and increased PD-L1 expression through activation of the PI3K/AKT signaling pathway, influencing the efficacy of PD-1 inhibitors.\"}]","The role and mechanism of ARID1A in immunotherapy of gastric cancer | PDF",1790172363,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20efadf682449e6fea50495f0507b136.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3dd19d7b75946a0aefc675c407bcde38.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92f03eb471ef4ad2f165e78fc3bc04ba.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c43ceb721e525a89b8d9b99dfff1573.webp",980,1301]